耐多药潜伏结核治疗的系统评价与成本效果
该系统评价纳入1994至2014年21篇文章,分析耐多药潜伏结核感染接触者治疗后的结核发病率、治疗完成与中断及成本效果。结果显示治疗使耐多药结核发病率降低约90%(9%-99%),但含吡嗪酰胺方案因不良反应中断率高,氟喹诺酮联合乙胺丁醇方案成本效果最佳。
要点
- 耐多药潜伏结核治疗可降低结核发病风险,估计降幅90%(9%-99%)
- 含吡嗪酰胺方案因不良反应导致治疗中断率高
- 氟喹诺酮联合乙胺丁醇方案成本效果最佳
核心结论
- 治疗耐多药潜伏结核可降低结核发病率,提示能有效预防进展为耐多药结核,并确认成本效果。
- 含吡嗪酰胺的耐多药潜伏结核方案常因不良反应导致治疗中断。
研究设计与样本
- 纳入21篇符合标准文章,其中6篇比较治疗与未治疗接触者,10篇仅报告治疗者,5篇仅报告未治疗者。
- 将接触者耐多药潜伏结核有效治疗定义为使用至少一种其耐多药结核菌株可能敏感的藥物。
主要发现
- 基于5项比较研究,耐多药结核发病率估计降低90%(95%CI 9%-99%)。
- 含吡嗪酰胺方案的治疗中断率高,原因为不良反应。
- 氟喹诺酮联合乙胺丁醇方案的成本效果最大。
关键数值与推荐
- 耐多药结核发病率降低90%(95%CI 9%-99%),基于5项比较研究。
- 有效治疗定义为至少使用一种其耐多药结核菌株可能敏感的藥物。
临床怎么用
- 对耐多药结核感染接触者的潜伏结核治疗可考虑用于预防进展为耐多药结核。
- 选择方案时需权衡不良反应导致的中断风险,含吡嗪酰胺方案中断率高。
- 氟喹诺酮联合乙胺丁醇方案具有最佳成本效果。
局限性
- 符合纳入标准的研究较少,结果应谨慎解读。
- 已发表数据主要由小型观察性研究组成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND.: Evidence-based recommendations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published data consist of small observational studies. Tuberculosis incidence in persons treated for latent MDR -TB infection is unknown. METHODS.: We conducted a systematic review of studies published 1 January 1994-31 December 2014 to analyze TB incidence, treatment completion and discontinuation, and cost-effectiveness. We considered contacts with LTBI effectively treated if they were on ≥1 medication to which their MDR-TB strain was likely susceptible. We selected studies that compared treatment vs nontreatment outcomes and performed a meta-analysis to estimate the relative risk of TB incidence and its 95% confidence interval. RESULTS.: We abstracted data from 21 articles that met inclusion criteria. Six articles presented outcomes for contacts who were treated compared with those not treated for MDR-LTBI; 10 presented outcomes only for treated contacts, and 5 presented outcomes only for untreated contacts. The estimated MDR-TB incidence reduction was 90% (9%-99%) using data from 5 comparison studies. We also found high treatment discontinuation rates due to adverse effects in persons taking pyrazinamide-containing regimens. Cost-effectiveness was greatest using a fluoroquinolone/ethambutol combination regimen. CONCLUSIONS.: Few studies met inclusion criteria, therefore results should be cautiously interpreted. We found a reduced risk of TB incidence with treatment for MDR-LTBI, suggesting effectiveness in prevention of progression to MDR-TB, and confirmed cost-effectiveness. However, we found that pyrazinamide-containing MDR-LTBI regimens often resulted in treatment discontinuation due to adverse effects.
引用
- Marks SM, Mase SR, Morris SB, et al. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2017. PMID: 28329197. doi:10.1093/cid/cix208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。